Small-Scale Models for ATMP Validation


Small-Scale Models for ATMP Validation

Published on 29/11/2025

Small-Scale Models for ATMP Validation

Advanced Therapy Medicinal Products (ATMPs) represent a groundbreaking shift in biopharmaceuticals. Their complexity requires a nuanced approach to validation, particularly in the context of Process Performance Qualification (PPQ) and Contingent Process Validation (CPV). This article will guide you through the step-by-step processes of utilizing small-scale models for ATMP validation, focusing on viral clearance validation, spiking studies, and effective controls in closed systems and single-use systems in compliance with aseptic controls as outlined in Annex 1.

Understanding Advanced Therapy Medicinal Products (ATMPs)

Advanced Therapy Medicinal Products (ATMPs) encompass gene therapies, somatic cell therapies, and tissue-engineered products. These therapies, often derived from human cells, require rigorous validation processes to ensure safety, efficacy, and quality throughout their lifecycle. The increasing complexity of ATMPs necessitates advanced strategies for validating their manufacturing processes. Key steps include identifying potency and identity Critical Quality Attributes (CQAs) and establishing a robust chain of identity custody (COI).

Importance of Validation in ATMP Development

Validation under Good Manufacturing Practice (cGMP) standards is essential in the production of ATMPs to confirm that the processes yield a product that consistently meets predetermined specifications. Validation activities allow for risk management by identifying potential challenges and establishing control measures.

  • Process Performance Qualification (PPQ): PPQ is the critical final step in process validation that ensures the manufacturing process consistently produces a product of acceptable quality.
  • Contingent Process Validation (CPV): This approach includes the ongoing assessment of process performance post-PPQ to identify any deviations.
  • Viral Clearance Validation: This involves confirming that any viral contaminants are effectively removed or inactivated during manufacturing.

Step-by-Step Guide to PPQ and CPV Tailoring for ATMPs

Tailoring PPQ and CPV processes for ATMPs requires a clear understanding of both regulatory expectations and the unique characteristics of the products being developed. The following steps outline a structured approach to ensure compliance with regulatory guidance, such as that provided by the FDA and EMA.

Step 1: Define Critical Quality Attributes (CQAs)

The first step in PPQ is the definition of Critical Quality Attributes (CQAs) relevant to the intended use of the ATMP. Potency identity CQAs must be identified early and may include:

  • Purity
  • Potency
  • Identity

Defining these CQAs involves comprehensive risk assessments and must comply with ICH Q5A(R2) guidelines to ensure that they are sufficiently broad yet specific enough to assess product quality effectively.

Step 2: Develop a Process Flow Diagram

Creating a process flow diagram allows for visualization of the entire manufacturing process, which aids in identifying the key steps where validation will be performed. This diagram should include:

  • Raw material sourcing and testing
  • Cell culture and expansion
  • Product harvesting
  • Filtration and purification
  • Filling and finishing

This step ensures that every segment of the process is scrutinized for potential risks and quality assurance points.

Step 3: Establish and Validate Control Strategies

Control strategies outline the measures taken to ensure that manufacturing processes consistently produce quality products. These should include:

  • Process parameters: Temperature, pressure, and time requirements for each step.
  • Quality parameters: Defined thresholds for CQAs, especially concerning viral clearance validation.
  • System controls: Implementation of closed systems and single-use systems can significantly enhance sterility assurance and limit contamination exposure.

Utilizing closed systems or single-use systems can reduce the risk of interference from environmental contaminants and facilitate easier maintenance of aseptic conditions as specified in Annex 1 guidelines.

Viral Clearance Validation in ATMPs

Viral clearance validation is a pivotal component in the lifecycle of ATMPs, ensuring that any viral contaminants are adequately removed or inactivated during the manufacturing process. This validation process typically involves those described in regulatory documents such as ICH Q5A(R2) and requires adherence to rigorous methodologies, including spiking studies.

Step 4: Performing Spiking Studies

Spiking studies serve as a fundamental method for assessing viral clearance during the manufacturing process. These studies involve intentionally adding known quantities of viruses into a batch of product and then analyzing how effectively the process removes or inactivates these contaminants. The typical steps involved are:

  • Selection of Virus: Select appropriate model viruses based on their size, structure, and behavior in relation to the specific processes to evaluate the effectiveness of removal or inactivation.
  • Define Dosing: Establish appropriate levels of viral spiking based on worst-case scenarios, considering factors such as the viral titer and type of therapeutics produced.
  • Validation of Analytical Method: Ensure that the analytical techniques employed can accurately determine viral levels pre- and post-manufacturing.

Once the spiking studies are carried out, the data must be analyzed to evaluate the extent of viral clearance through quantitative assessments. This data becomes an essential part of the regulatory submission for your ATMP.

Implementing a Chain of Identity Custody (COI)

The implementation of a Chain of Identity (COI) custody is critical for the integrity of ATMPs, particularly those derived from patient materials. Establishing robust tracking and documentation procedures ensures that every step of the manufacturing process maintains identity linkage throughout:

Step 5: Documentation Practices

  • Sourcing: Implement traceability for raw material sources, documenting every transfer and transformation of biological materials.
  • Tracking: Utilize barcoding systems or digital tracking tools to maintain continuous records from material sourcing through processing to final product.
  • Storage: Ensure that conditions of storage are monitored and documented consistently to avoid any identity mix-ups.

Creating a comprehensive system enables consistent tracking and enhances risk management concerning patient material traceability. It is essential for fulfilling regulatory requirements set forth by bodies like the FDA and EMA.

Closing Considerations for Successful Validation

In conclusion, the validation of Advanced Therapy Medicinal Products (ATMPs) is a complex yet crucial aspect of pharmaceutical development that requires meticulous planning, execution, and documentation. By following this step-by-step guide, professionals can tailor PPQ and CPV processes to meet both regulatory expectations and the unique demands of ATMP production. As the field of biologics continues to advance, remaining aligned with guidelines such as those set forth in ICH Q5A(R2) and complying with standards outlined in aseptic controls in Annex 1 will ensure that novel therapies are safe and effective for patient care. Regular engagement with regulatory updates is advised for all pharma professionals involved in ATMP development.